Biocon Group company information, Employees & Contact Information

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara® Yahoo! Finance Canada

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio PR Newswire

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% Biocon

Biocon Biologics Receives Health Canada Approval for GlobeNewswire

Biocon's new US facility clears key FDA hurdle The New Indian Express

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey The AI Journal

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases Yahoo Finance

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% Biocon

Biocon Biologics gets EU approval for Vevzuo and Evfraxy biosimilars ET Now

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr Biocon

Investors Biocon

Our work in Biosimilars Biocon

Legacy - Biocon - Global Biopharmaceutical company Biocon

Research Services - Turning clients’ ideas into meaningful innovation Biocon

Biocon Q2FY25 Revenue at Rs 3,623 Cr, EBITDA at Rs 718 Cr Biocon

Quality & Compliance Biocon

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business Biocon

Biocon Malaysia - Asia’s largest insulin manufacturing and R&D facility Biocon

KEY MANAGEMENT TEAM Biocon

Functions - Biocon - Global Biopharmaceutical company Biocon

BOARD OF DIRECTORS Biocon

Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide Biocon

Biosimilars - Making potentially life-saving drugs affordable & accessible Biocon

EXECUTIVE LEADERSHIP TEAM Biocon

LEADERSHIP TEAM Biocon

Global Scale Manufacturing Biocon

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr Biocon

RESEARCH & DEVELOPMENT Biocon

Wide Global Footprint - U.S., Canada, EU, Japan, Latin America, Africa Biocon

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States GlobeNewswire

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options PR Newswire

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52% Biocon

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars PR Newswire

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars PR Newswire

Biocon Foundation - Real progress impacts everyone Biocon

Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ Biocon

Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31% Biocon

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis Business Wire

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe GlobeNewswire

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers Biocon

Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection PR Newswire

Freshers Biocon Biologics Internship Applications Open For MSc Biotech, Biochem BioTecNika

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024 PR Newswire UK

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe PR Newswire UK

European agency endorses approval of Biocon Biologics’ biosimilar Ustekinumab The New Indian Express

Biocon Q2 net profit declines 84 per cent to Rs 27.1 crore The New Indian Express

Biocon Biologics' arm gets USD 90 million contract from Malaysia for supply of insulins The New Indian Express

Biocon's Nationwide 'Winning with Diabetes' Campaign Raises Awareness on Disease Prevention & Management PR Newswire

Biocon arm closes multi-billion buyout The New Indian Express

Biocon reports loss of Rs 16 crore on account of higher tax The New Indian Express

NeoBiocon Partners With Novartis to Offer Vildagliptin for Diabetics in UAE PR Newswire

BIOCON Stock Price and Chart — NSE:BIOCON TradingView

Exclusive | Biocon, Mylan Biosimilar Deal in Last Leg; Serum Institute to Buy Additional Stake of $500 Mill News18

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business ANI News

Biocon shares jump as unit signs long-term deal with Eris Lifesciences Zee Business

Biocon Q2FY23 Revenue at Rs 2,384 Cr., Up 23 percent; Core EBITDA at Rs 816 Cr., Up 34 percent Gross R&D Spend at Rs 252 Crore, Up 52 percent ANI News

Mr Rakesh Bamzai steps down as Biocon's marketing president BioSpectrum India

Biocon Share Price Target 2025, 2026, 2030, 2050 shareprice-target.com